Baltazar Gomez-Mancilla

This inventor holds 9 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignee: Novartis Ag. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Baltazar Gomez-Mancilla. Retrieved from https://idiyas.com/inventor/baltazar-gomez-mancilla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 12)

% Patents Active = 77.8

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 17)

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 8(Granted Patents)

Company Filing History:

9 out of 3,978

Novartis Ag

patents

Years Active: 2014-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678415 - Use of nicotinic acetylcholine receptor alpha 7 activators (2026-07-14),

2. 12215387 - Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment (2025-02-04),

3. 12201612 - Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use (2025-01-21),

4. 11878001 - Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use (2024-01-23),

5. 11359241 - Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment (2022-06-14),

6. 11096916 - Use of nicotinic acetylcholine receptor alpha 7 activators (2021-08-24),

7. 10537539 - Use of nicotinic acetylcholine receptor alpha 7 activators (2020-01-21),

8. 9828642 - Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment (2017-11-28),

9. 8703809 - Combination products (2014-04-22),

Title: Baltazar Gomez-Mancilla: Innovator in Neuropharmacology

Introduction

Baltazar Gomez-Mancilla is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of neuropharmacology, holding a total of eight patents. His work focuses on developing innovative treatments for cognitive impairments and alcohol use disorders.

Latest Patents

One of his latest patents is titled "Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment." This invention provides methods for predicting therapeutic responsiveness in subjects suffering from cognitive impairments or neurodegenerative disorders. Another notable patent is "Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use." This invention relates to the use of mavoglurant in reducing alcohol use and preventing relapse in patients with alcohol use disorders.

Career Highlights

Baltazar Gomez-Mancilla is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical industry.

Collaborations

He has collaborated with notable colleagues, including Donald Johns and Dominik Feuerbach, to advance research in his field.

Conclusion

Baltazar Gomez-Mancilla's innovative work in neuropharmacology and his contributions to the treatment of cognitive impairments and alcohol use disorders highlight his importance as an inventor. His patents reflect a commitment to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.